G1 Therapeutics (GTHX) Stock Forecast, Price Target & Predictions
GTHX Stock Forecast
G1 Therapeutics stock forecast is as follows: an average price target of $4.50 (represents a -37.06% downside from GTHX’s last price of $7.15) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
GTHX Price Target
The average price target for G1 Therapeutics (GTHX) is $4.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $3.00. This represents a potential -37.06% downside from GTHX's last price of $7.15.
GTHX Analyst Ratings
According to 8 Wall Street analysts, G1 Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GTHX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (50.00%), 4 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
G1 Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | Gil Blum | Needham | $6.00 | $2.22 | 170.27% | -16.08% |
| Jun 25, 2024 | Edward White | H.C. Wainwright | $3.00 | $2.22 | 35.14% | -58.04% |
The latest G1 Therapeutics stock forecast, released on Jun 25, 2024 by Gil Blum from Needham, set a price target of $6.00, which represents a 170.27% increase from the stock price at the time of the forecast ($2.22), and a -16.08% decrease from GTHX last price ($7.15).
G1 Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $4.50 | $4.50 |
| Last Closing Price | $7.15 | $7.15 | $7.15 |
| Upside/Downside | -100.00% | -37.06% | -37.06% |
In the current month, the average price target of G1 Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to G1 Therapeutics's last price of $7.15. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | Raymond James | - | Market Perform | Downgrade |
| Aug 07, 2024 | Wedbush | Buy | Neutral | Downgrade |
| Aug 07, 2024 | Needham | Buy | Hold | Downgrade |
| Aug 07, 2024 | Rodman & Renshaw | - | Neutral | Downgrade |
| Jun 25, 2024 | Evercore ISI | - | Outperform | Upgrade |
| Jun 25, 2024 | Wells Fargo | - | Overweight | Upgrade |
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 13, 2024 | Needham | Buy | Buy | Hold |
| Jun 13, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
G1 Therapeutics's last stock rating was published by Raymond James on Aug 07, 2024. The company Downgrade its GTHX rating from "null" to "Market Perform".
G1 Therapeutics Financial Forecast
G1 Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.87M | $12.30M | $42.39M | $12.95M | $10.25M | $23.58M | - | $6.90M | $5.80M | $4.86M | $6.60M | $14.22M | $16.55M | $26.60M |
| Avg Forecast | $25.50M | $24.43M | $23.33M | $22.23M | $21.09M | $19.94M | $18.79M | $17.65M | $26.12M | $24.21M | $22.71M | $20.95M | $23.02M | $17.69M | $16.26M | $15.21M | $13.08M | $14.24M | $28.95M | $11.17M | $9.66M | $23.33M | $9.14M | $6.37M | $5.71M | $4.78M | $2.77M | $775.00K | $4.64M | $28.57M |
| High Forecast | $27.71M | $26.55M | $25.35M | $24.15M | $22.91M | $21.67M | $20.41M | $19.18M | $28.38M | $26.30M | $24.68M | $22.76M | $25.01M | $18.36M | $17.66M | $16.53M | $14.60M | $15.47M | $31.45M | $12.14M | $10.50M | $25.35M | $9.14M | $6.83M | $6.12M | $5.12M | $2.97M | $830.20K | $4.97M | $30.61M |
| Low Forecast | $23.43M | $22.44M | $21.43M | $20.41M | $19.37M | $18.32M | $17.26M | $16.21M | $23.99M | $22.24M | $20.86M | $19.24M | $21.14M | $16.65M | $14.93M | $13.97M | $12.34M | $13.08M | $26.59M | $10.26M | $8.87M | $21.43M | $9.14M | $5.98M | $5.36M | $4.49M | $2.60M | $727.55K | $4.36M | $26.82M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 0.86% | 1.46% | 1.16% | 1.06% | 1.01% | - | 1.08% | 1.01% | 1.02% | 2.38% | 18.35% | 3.56% | 0.93% |
G1 Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $15.21M, with a low forecast of $13.97M, and a high forecast of $16.53M. GTHX's average Quarter revenue forecast represents a 2.27% increase compared to the company's last Quarter revenue of $14.87M (Dec 23).
G1 Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.20M | $-16.37M | $11.52M | $-24.51M | $-30.04M | $-21.15M | - | $-46.81M | $-37.60M | $-41.10M | $-38.16M | $-25.44M | $-23.99M | $-9.84M |
| Avg Forecast | $-12.61M | $-12.08M | $-11.54M | $-10.99M | $-10.43M | $-9.86M | $-9.29M | $-8.73M | $-12.92M | $-11.97M | $-11.23M | $-10.36M | $-11.38M | $-8.75M | $-8.04M | $-46.13M | $-6.47M | $-7.04M | $-14.32M | $-41.94M | $-4.78M | $-139.00M | $-4.52M | $-38.13M | $-40.89M | $-109.88M | $-38.95M | $-35.42M | $-30.12M | $-9.51M |
| High Forecast | $-11.59M | $-11.10M | $-10.60M | $-10.10M | $-9.58M | $-9.06M | $-8.53M | $-8.02M | $-11.87M | $-11.00M | $-10.32M | $-9.52M | $-10.46M | $-8.23M | $-7.38M | $-36.91M | $-6.10M | $-6.47M | $-13.15M | $-33.55M | $-4.39M | $-111.20M | $-4.52M | $-30.50M | $-32.71M | $-87.91M | $-31.16M | $-28.34M | $-24.10M | $-7.61M |
| Low Forecast | $-13.70M | $-13.13M | $-12.54M | $-11.94M | $-11.33M | $-10.72M | $-10.09M | $-9.49M | $-14.04M | $-13.01M | $-12.20M | $-11.26M | $-12.37M | $-9.08M | $-8.74M | $-55.36M | $-7.22M | $-7.65M | $-15.55M | $-50.33M | $-5.19M | $-166.80M | $-4.52M | $-45.75M | $-49.07M | $-131.86M | $-46.74M | $-42.50M | $-36.15M | $-11.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.89% | 2.32% | -0.80% | 0.58% | 6.29% | 0.15% | - | 1.23% | 0.92% | 0.37% | 0.98% | 0.72% | 0.80% | 1.03% |
4 analysts predict GTHX's average Quarter EBITDA for Sep 23 to be $-7.04M, with a high of $-6.47M and a low of $-7.65M. This is -161.15% lower than G1 Therapeutics's previous annual EBITDA (Jun 23) of $11.52M.
G1 Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.94M | $-18.20M | $8.71M | $-32.53M | $-33.65M | $-25.27M | - | $-51.60M | $-40.02M | $-42.47M | $-39.42M | $-26.44M | $-25.35M | $-11.67M |
| Avg Forecast | $5.79M | $5.11M | $4.42M | $3.72M | $2.49M | $1.76M | $1.03M | $325.35K | $5.25M | $3.67M | $2.80M | $-95.77K | $461.10K | $-5.00M | $-8.66M | $-48.48M | $-14.58M | $-17.88M | $-11.46M | $-44.07M | $-44.29M | $-143.64M | $-53.15M | $-40.06M | $-43.52M | $-113.55M | $-40.24M | $-36.82M | $-31.82M | $-11.28M |
| High Forecast | $6.44M | $5.69M | $4.92M | $4.13M | $2.77M | $1.96M | $1.15M | $361.92K | $5.84M | $4.09M | $3.11M | $-85.62K | $512.93K | $-2.08M | $-7.75M | $-38.78M | $-11.88M | $-15.98M | $-10.25M | $-35.26M | $-39.60M | $-114.91M | $-53.15M | $-32.05M | $-34.81M | $-90.84M | $-32.19M | $-29.46M | $-25.46M | $-9.03M |
| Low Forecast | $5.17M | $4.57M | $3.95M | $3.32M | $2.22M | $1.58M | $924.25K | $290.88K | $4.69M | $3.28M | $2.50M | $-106.53K | $412.25K | $-7.08M | $-9.64M | $-58.17M | $-15.66M | $-19.88M | $-12.75M | $-52.88M | $-49.27M | $-172.37M | $-53.15M | $-48.08M | $-52.22M | $-136.26M | $-48.29M | $-44.19M | $-38.19M | $-13.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 1.02% | -0.76% | 0.74% | 0.76% | 0.18% | - | 1.29% | 0.92% | 0.37% | 0.98% | 0.72% | 0.80% | 1.03% |
G1 Therapeutics's average Quarter net income forecast for Sep 23 is $-17.88M, with a range of $-19.88M to $-15.98M. GTHX's average Quarter net income forecast represents a -305.23% decrease compared to the company's last Quarter net income of $8.71M (Jun 23).
G1 Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.17M | $16.78M | $17.43M | $21.75M | $23.56M | $24.43M | - | $26.71M | $23.22M | $24.27M | $25.24M | $22.97M | $24.26M | $18.41M |
| Avg Forecast | $42.70M | $40.91M | $39.07M | $37.22M | $35.31M | $33.39M | $31.46M | $29.56M | $43.74M | $40.54M | $38.03M | $35.08M | $38.54M | $29.63M | $27.22M | $25.47M | $21.91M | $23.84M | $48.47M | $18.71M | $16.18M | $39.06M | $15.30M | $10.67M | $9.57M | $8.00M | $4.65M | $1.30M | $7.77M | $17.80M |
| High Forecast | $46.40M | $44.45M | $42.45M | $40.43M | $38.37M | $36.28M | $34.18M | $32.11M | $47.52M | $44.04M | $41.32M | $38.11M | $41.87M | $30.74M | $29.57M | $27.67M | $24.45M | $25.90M | $52.66M | $20.33M | $17.57M | $42.44M | $15.30M | $11.43M | $10.25M | $8.57M | $4.98M | $1.39M | $8.33M | $21.36M |
| Low Forecast | $39.22M | $37.58M | $35.89M | $34.18M | $32.44M | $30.67M | $28.89M | $27.15M | $40.17M | $37.23M | $34.93M | $32.22M | $35.40M | $27.88M | $25.00M | $23.39M | $20.66M | $21.90M | $44.52M | $17.18M | $14.86M | $35.88M | $15.30M | $10.02M | $8.98M | $7.51M | $4.36M | $1.22M | $7.30M | $14.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.70% | 0.36% | 1.16% | 1.46% | 0.63% | - | 2.50% | 2.43% | 3.03% | 5.43% | 17.70% | 3.12% | 1.03% |
G1 Therapeutics's average Quarter SG&A projection for Mar 24 is $25.47M, based on 4 Wall Street analysts, with a range of $23.39M to $27.67M. The forecast indicates a 67.93% rise compared to GTHX last annual SG&A of $15.17M (Dec 23).
G1 Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | - | $-0.63 | $-0.77 | $-0.59 | - | $-1.21 | $-0.94 | $-1.00 | $-0.94 | $-0.65 | $-0.67 | $-0.31 |
| Avg Forecast | $0.11 | $0.10 | $0.08 | $0.07 | $0.05 | $0.03 | $0.02 | $0.01 | $0.10 | $0.07 | $0.05 | $-0.00 | $0.01 | $-0.10 | $-0.17 | $-0.20 | $-0.28 | $-0.34 | $-0.22 | $-0.64 | $-0.84 | $-0.64 | $-1.02 | $-0.98 | $-1.03 | $-1.02 | $-0.98 | $-1.07 | $-0.90 | $-0.30 |
| High Forecast | $0.12 | $0.11 | $0.09 | $0.08 | $0.05 | $0.04 | $0.02 | $0.01 | $0.11 | $0.08 | $0.06 | $-0.00 | $0.01 | $-0.04 | $-0.15 | $-0.18 | $-0.23 | $-0.30 | $-0.20 | $-0.57 | $-0.75 | $-0.57 | $-1.02 | $-0.90 | $-0.95 | $-0.94 | $-0.90 | $-0.99 | $-0.83 | $-0.28 |
| Low Forecast | $0.10 | $0.09 | $0.08 | $0.06 | $0.04 | $0.03 | $0.02 | $0.01 | $0.09 | $0.06 | $0.05 | $-0.00 | $0.01 | $-0.13 | $-0.18 | $-0.22 | $-0.30 | $-0.38 | $-0.24 | $-0.71 | $-0.94 | $-0.71 | $-1.02 | $-1.07 | $-1.13 | $-1.11 | $-1.07 | $-1.17 | $-0.98 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | -0.00% | 0.98% | 0.91% | 0.92% | - | 1.23% | 0.91% | 0.98% | 0.96% | 0.61% | 0.75% | 1.02% |
According to 4 Wall Street analysts, G1 Therapeutics's projected average Quarter EPS for Sep 23 is $-0.34, with a low estimate of $-0.38 and a high estimate of $-0.30. This represents a -170425.00% decrease compared to GTHX previous annual EPS of - (Jun 23).
G1 Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SGMO | Sangamo Therapeutics | $0.85 | $12.00 | 1311.76% | Hold |
| FATE | Fate Therapeutics | $4.02 | $39.75 | 888.81% | Buy |
| ALLO | Allogene Therapeutics | $2.96 | $29.00 | 879.73% | Buy |
| CHRS | Coherus BioSciences | $1.30 | $9.00 | 592.31% | Hold |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| HRTX | Heron Therapeutics | $1.87 | $7.00 | 274.33% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| MGNX | MacroGenics | $3.70 | $10.33 | 179.19% | Hold |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| RCUS | Arcus Biosciences | $17.95 | $35.20 | 96.10% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| AXSM | Axsome Therapeutics | $93.67 | $117.83 | 25.79% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| ATRA | Atara Biotherapeutics | $9.72 | $10.50 | 8.02% | Sell |
| GTHX | G1 Therapeutics | $7.15 | $4.50 | -37.06% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
GTHX Forecast FAQ
Is G1 Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, G1 Therapeutics (GTHX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 50.00% of GTHX's total ratings.
What is GTHX's price target?
G1 Therapeutics (GTHX) average price target is $4.5 with a range of $3 to $6, implying a -37.06% from its last price of $7.15. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will G1 Therapeutics stock go up soon?
According to Wall Street analysts' prediction for GTHX stock, the company can go down by -37.06% (from the last price of $7.15 to the average price target of $4.5), down by -16.08% based on the highest stock price target, and down by -58.04% based on the lowest stock price target.
Can G1 Therapeutics stock reach $11?
GTHX's average twelve months analyst stock price target of $4.5 does not support the claim that G1 Therapeutics can reach $11 in the near future.
What are G1 Therapeutics's analysts' financial forecasts?
G1 Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $77.47M (high $84.17M, low $71.16M), average EBITDA is $-38.315M (high $-35.193M, low $-41.628M), average net income is $5.61M (high $6.24M, low $5.02M), average SG&A $129.72M (high $140.94M, low $119.15M), and average EPS is $0.107 (high $0.119, low $0.0956). GTHX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $95.5M (high $103.76M, low $87.72M), average EBITDA is $-47.23M (high $-43.382M, low $-51.314M), average net income is $19.03M (high $21.17M, low $17.02M), average SG&A $159.9M (high $173.73M, low $146.87M), and average EPS is $0.363 (high $0.403, low $0.324).
Did the GTHX's actual financial results beat the analysts' financial forecasts?
Based on G1 Therapeutics's last annual report (Dec 2023), the company's revenue was $82.51M, beating the average analysts forecast of $67.44M by 22.34%. Apple's EBITDA was $-39.527M, missing the average prediction of $-69.766M by -43.34%. The company's net income was $-47.967M, missing the average estimation of $-87.995M by -45.49%. Apple's SG&A was $71.13M, missing the average forecast of $112.93M by -37.01%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.477 by -99.94%. In terms of the last quarterly report (Dec 2023), G1 Therapeutics's revenue was $14.87M, beating the average analysts' forecast of $13.08M by 13.68%. The company's EBITDA was $-25.195M, beating the average prediction of $-6.471M by 289.37%. G1 Therapeutics's net income was $-5.94M, missing the average estimation of $-14.584M by -59.27%. The company's SG&A was $15.17M, missing the average forecast of $21.91M by -30.77%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.278 by -99.96%